Articles tagged "Cytomeglovirus"

2022 American Transplant Congress
Mass Cytometry Reveals Single-cell Kinetics Of Cytotoxic Lymphocyte Evolution In Cmv-infected Renal Transplant Patients
K. Ishiyama¹, J. Arakawa-Hoyt¹, O. Aguilar¹, T. Sigdel¹, S. Tamaki¹, J. Babdor¹, M. Spitzer¹, E. Reed², M. Sarwal³, L. Lanier¹
¹UCSF, San Francisco, CA, ²Univ of California LA, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA
*Purpose: Cytomegalovirus (CMV) infection is associated with graft rejection in renal transplantation. Memory-like NK cells expressing NKG2C and lacking FcεRIγ are established during CMV infection.*Methods:…
2022 American Transplant Congress
Cytomegalovirus Prophylaxis in Pediatric Liver Transplantation: A Comparison of Strategies Across the SPLIT Consortium
E. D. Knackstedt¹, S. G. Anderson², R. Anand², J. Mitchell², J. Bucuvalas³, L. Danziger-Isakov⁴
¹Univ of Utah/Primary Children's Hosp, SLC, UT, ²Emmes, Rockville, MD, ³Icahn School of Med at Mount Sinai, New York City, NY, ⁴Cincinnati Children's Hosp Med Ctr, Cincinnati, OH
*Purpose: To compare the effectiveness of short (180d) cytomegalovirus (CMV) prophylaxis in pediatric liver transplantation (pLTX).*Methods: A prospective cohort study of primary pLTX (≤18 yrs…
2022 American Transplant Congress
Evaluation of Prophylactic Valganciclovir Dosing in Kidney Transplant Recipients at an Urban Transplant Institution
E. Foster¹, D. Pierce¹, T. Cairns¹, S. Borgetti², I. Tzvetanov³, E. Benedetti³, C. Muran¹
¹Pharmacy, University of Illinois at Chicago, Chicago, IL, ²Medicine, University of Illinois at Chicago, Chicago, IL, ³Surgery, University of Illinois at Chicago, Chicago, IL
*Purpose: Dosing and duration of cytomegalovirus (CMV) prophylaxis with valganciclovir (VGC) in kidney transplant (KT) recipients is variable by transplant center. Prior studies have shown…
2022 American Transplant Congress
Circulating Plasma Proteomics Analysis of CMV Infection in Kidney Transplantation
T. Sigdel¹, P. Boada¹, D. Gjertson², M. Rossetti², B. Fatou³, H. Steen³, J. Schaenman², S. Bunnapradist², E. Reed², M. Sarwal¹
¹UCSF, San Francisco, CA, ²UCLA, Los Angeles, CA, ³Harvard Medical School, Boston, MA
*Purpose: Cytomegalovirus (CMV) infection is a threat to kidney transplantation. We studied circulating host proteome perturbations due to CMV infection in kidney transplantation as it…
2022 American Transplant Congress
Does a Second Transplant Increase the Risk for CMV Infection? An Evaluation of the Incidence of CMV Viremia in the Previously Transplanted Kidney Recipient
J. Byrns¹, G. Katz-Greenberg²
¹Pharmacy, Duke University Hospital, Durham, NC, ²Medicine, Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) viremia is a common complication of kidney transplant recipients (KTR) with significant morbidity/mortality. Patients who receive multiple transplants are potentially at a…
2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
F. Silveira¹, S. Haider², D. Kaul³, O. Witzke⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Pittsburgh, Pittsburgh, PA, ²McMaster Univ., Hamilton, ON, Canada, ³Univ. Michigan, Ann Arbor, MI, ⁴Univ. Duisburg-Essen, Essen, Germany, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…
2022 American Transplant Congress
Impact of Cytomegalovirus Infection on mRNA Expression Utilizing the Molecular Microscope in Heart Transplant Recipients
S. S. Patlolla, J. Van Zyl, K. Castro, S. Mckean, R. Patel, S. Carey, A. Alam, S. Hall
Cardiology, Baylor University Medical Center, Dallas, TX
*Purpose: Little is known about the effect of CMV infection on transplant messenger RNA expression utilizing the molecular microscope (MMDx) in the absence of acute…
2022 American Transplant Congress
Assessment of Letermovir as Universal Prophylaxis for Cytomegalovirus Infection in Lung Transplant Recipients
L. F. Borges, T. Sparkman, K. Gutierrez, J. Banbury
UAB Hospital, Birmingham, AL
*Purpose: Cytomegalovirus (CMV) poses a significant concern in the post-operative management of lung transplant (LT) recipients. Current recommended prophylactic strategies with ganciclovir (GCV) or valganciclovir…
2022 American Transplant Congress
The Effect of Late-Onset Cytomegalovirus Infection on the Outcome of Renal Allograft in Patients with Delayed Graft Function
M. Rahimi Shahmirzadi¹, M. Silverman¹, L. Gunaratnam², A. Jevnikar², A. A. House², S. Hosseini-Moghaddam³
¹Infectious Diseases Care Program, St. Joseph's Health Care London, London, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Health Care London, London, ON, Canada
*Purpose: Delayed graft function (DGF) has been reported to increase the risk of renal allograft loss. The role of late-onset Cytomegalovirus infection in the association…
2022 American Transplant Congress
Analysis of Induction Dose and Incidence of CMV Viremia in High Risk (HR; D+/R-) Renal Transplant Recipients
K. Shimko, M. Pittappilly, R. Chowdhury, H. Karimi, C. Puttarajappa, M. Wijkstrom, R. Mehta
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Depleting induction puts patients at risk of opportunistic infections. Our protocol aims for 5-6mg/kg cumulative dose of antithymocyte globulin(ATG) divided over 4 doses. It…

1
2
3
…
33
Next Page »